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The following educational supplement on “Controversies
in Diffuse Large B Cell Lymphoma” addresses three primary
areas. The ﬁrst section, “Biology of Diffuse Large B Cell
Lymphomas,” focuses on recent advances in understanding
the pathogenesis and biology of this disorder with a spotlight
on new classiﬁcation methods that should lead to improved
understanding and treatment of this disease. The second
section, “State of Salvage Therapy for Relapsed and Primary
Refractory Diffuse Large B Cell Lymphoma,” addresses recent
trials that have provided a new benchmark for outcomes of
patients undergoing autologous hematopoietic stem cell
transplantation (HSCT) after failing initial therapy with
rituximab-containing induction regimens. This section
reviews some of the new prognostic data that will help
categorize patients into those with a good or poor prognosis
after autologous HSCT and how novel salvage regimens are
needed to improve these results. The third section, “Hema-
topoietic Stem Cell Transplantation Conditioning Regimens
and Post-Transplant Maintenance Therapy for Diffuse Large
B-Cell Lymphoma,” assesses outcomes achieved with
a variety of novel and conventional conditioning regimens,
including the use of radioimmunotherapy and allogeneic
HSCT for poor-prognosis patients. This section also describes
potential uses for new agents as maintenance therapy after
autologous HSCT.
BIOLOGY OF DIFFUSE LARGE B CELL LYMPHOMAS
Randy D. Gascoyne
Diffuse, aggressive, large B cell lymphomas represent
the most frequent histological subtype of non-Hodgkin
lymphoma encountered in clinical practice in North
America. This category includes a spectrum of lymphoma
entities, the most common of which is diffuse large B cell
lymphoma (DLBCL), not otherwise speciﬁed. Also included
are distinct entities and subtypes such as primary medias-
tinal large B cell lymphoma (PMBCL), plasmablastic
lymphoma, primary central nervous system DLBCL, and T
cell/histiocyte-rich large B cell lymphoma, to name but a few.Normal Germinal Center
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antigen induces a T-dependent antibody response, then
germinal center formation occurs and represents the
anatomical site for the ﬁnal steps in the generation of anti-
body diversity. Two important genetic mechanisms occur
within the germinal center, including somatic hyper-
mutation and class switch recombination. Both processes
require double-stranded DNA breaks and the presence of
activation-induced cytidine deaminase. Differentiation
through the germinal center is orchestrated by a number of
key transcription factors, including BCL6, PRDM1, IRF4, and
XBP1. B cells that survive re-express BCL2 and are selected
because they possess high-afﬁnity antibody on their surface.
These cells exit the germinal center and further differentiate
into either mature plasma cells or long-lived memory B cells.
Thus, the germinal center is largely responsible for gener-
ating both components of long-lived humoral immunity. This
complex biology is required to optimize the diversity of our
immune response but is equally fraught with errors, some of
which lead to the development of B cell non-Hodgkin
lymphomas [1].Diffuse Large B Cell Lymphomas
Gene Expression Proﬁling (GEP) has established the
presence of at least 3 main molecular subtypes of DLBCL,
including the germinal center B cell type (GCB), the acti-
vated B cell type (ABC), and PMBCL based on the stage of
B cell differentiation and presumed cell-of-origin [2]. GCB
and ABC together comprise 80% of all DLBCL cases and are
associated with differences in survival, genetics, and
mutational proﬁles highlighting distinct biology (Figure 1).
These cell-of-origin distinctions can have a differential
impact on the response to novel therapies that are
beginning to make their way into the upfront treatment
regimens used for this group of malignancies. Lessons
learned from a thorough understanding of the biology
inform on rational treatment approaches and a path
forward for more targeted therapies. Immunohistochem-
ical algorithms have been developed as surrogate testing
strategies for determining cell-of-origin, because Affyme-
trix GEP (Santa Clara, CA) requires frozen tissue that is
generally not available in routine clinical practice. The
most popular, the Hans algorithm, is based on 3 routine
immunohistochemical stains, CD10, BCL6, and MUM1, and
is variably associated with outcome, in part because it is
a 2-class predictor (GCB versus non-GCB) that tries to
recapitulate a three-class GEP predictor (GCB versus ABC
versus unclassiﬁable) but is also fraught with technicalTransplantation.
Figure 1. Critical events in the pathogenesis of DLBCL are depicted. For each of the 4 major molecular entities, the more frequent copy number alterations are shown
as well as recurrent mutations. The ABC subtype is thought to arise from a cell just before germinal center exit, having some features of plasmablasts. Both copy
number changes and recurrent mutations drive the 3 major themes in ABC pathogenesis, namely constitutive NF-kB signaling, chronic B cell receptor (BCR) signaling,
and a block in terminal B cell differentiation to mature plasma cells. The pathogenic events that underlie both PMBCL and nodular sclerosis Hodgkin lymphoma
(NSHL) are similar and include up-regulated JAK-STAT signaling and molecular events that foster immune privilege.
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development of a robust testing strategy for distinguishing
cell-of-origin subtypes is now of paramount importance.
The GCB subtype of DLBCL accounts for roughly 50% of all
cases, shows a favorable outcome, and reveals a gene
expression program reminiscent of normal germinal center B
cells. Cases harboring the t(14;18) are only found within the
GCB subtype of DLBCL. Recurrent mutations of EZH2,
TNFRSF14, MEF2B, GNA13, and SGK1 are all found to be highly
enriched within this category [4]. Next-generation
sequencing approaches have been used to uncover an
infrequent, but novel, gene fusion in GCB. Cases with
t(3;3)(q26.32;q28) fuses TBL1XR1 to TP63 and, interestingly,
the presence of this translocation was associated with GCB
cases that were primarily refractory to R-CHOP therapy [5].
The ABC subtype is recognized to have constitutive NF-kB
activation on the basis of gene expression and the pattern of
recurrent, somatic mutations found. Recurrent mutations in
CARD11, MYD88, and CD79B are found within the ABC
subtype, suggesting that constitutive signaling downstream
of the B cell receptor is important for ABC biology and
a logical target for more speciﬁc therapies [2]. Phase II data
and emerging phase III trials have shown that new agents
such as the proteosome inhibitor bortezomib, ibrutinib tar-
geting Bruton’s tyrosine kinase, fostamatinib targeting SYK,
CAL-101 targeting phosphatidylinositol 3-kinase, and lena-
lidomide all seem to be most effective against ABC cases [2].
Base paireresolution next-generation sequencing data
have also shown that histone modiﬁcation and epigenetic
chromatin remodeling are critical new aspects of DLBCL
biology not previously appreciated. The discovery of recur-
rent mutations in EZH2, a member of the polycomb repressorcomplex-2 responsible for laying down repressive chromatin
marks that silence gene expression, was found to be recur-
rently mutated in 22% of GCB DLBCL cases [6]. Mutations are
also found in follicular lymphoma, whereas loss-of-function
alterations characterize myeloid neoplasms. In follicular
lymphoma and DLBCL they were clearly established as gain-
of-function mutations. All EZH2 mutations in DLBCL are
heterozygous, requiring the presence of the wild-type allele
to produce the altered phenotype. The mutant allele accel-
erates the addition of the second and third methyl groups to
H3K27 lysine residues of core histones, but only if the wild-
type enzyme adds the ﬁrst methyl group [7]. Recurrent
mutations were also discovered to involve additional genes
involved in histone modiﬁcation, including MLL2, CREBBP,
EP300, MEF2B, and SETD2. In aggregate, these ﬁndings clearly
implicate an unprecedented role for histone modiﬁcation
and chromatin remodeling in the pathogenesis of DLBCL and,
importantly, highlight novel targets for therapy in selected
patients harboring these alterations.
Recurrent mutation in another group of genes has served
to refocus attention on the importance of immune escape as
an oncogenic driver in DLBCL pathobiology. Based on GEP
studies, the Leukemia LymphomaMolecular Proﬁling Project
(LLMPP) consortium showed that non-neoplastic immune
cells in DLBCL were important contributors to survival after
R-CHOP therapy [8]. A gene signature implicating macro-
phages, connective tissue elements, and myeloid precursors
(stromal-1) was associated with favorable outcome, whereas
a gene signature of angiogenesis and adipocytes (stromal-2)
was associated with inferior survival. The LLMPP had earlier
established that tumors with decreased expression of human
leukocyte antigen (HLA)-DR (major histocompatibility
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inferior outcomes. Recurrent mutations and other genetic
alterations of a number of genes, including CD58, B2M,
TNFRSF14, CD273, CD274, CIITA, TNFSF9, and several HLA
genes, clearly now implicate that escape from immuno-
surveillance is an important mechanism underlying the
pathogenesis of these tumors [4,9].
Translocation of the MYC oncogene can be seen in 6% to
14% of de novo DLBCL cases and is also associated with
inferior survival [10,11]. Importantly, expression of MYC
protein occurs in many more cases and when seen together
with BCL2 protein expression is associated with diminished
survival [12,13].
Finally, next-generation sequencing techniques were
recently used to identify a recurrent gene fusion in PMBCL,
accounting for nearly 40% of all cases and associated with
inferior survival [14]. CIITA is common to all fusions, is
located on chromosome 16p, and is the master transcrip-
tional controller of major histocompatibility complex class II
expression (ie, HLA-DR). The recurrent fusions implicate
CIITA as a promiscuous gene, but in 50% of the cases the
fusion partner involves the ligands of PD-1 located on
chromosome 9p24, PD-L1 (CD274), and PD-L2 (CD273) that
produce T cell exhaustion for the inﬁltrating T cells in the
tumor microenvironment. This novel mechanism produces
an “immunological double hit,” whereby both partners in
a gene fusion promote immune privilege by allowing the
tumor cells to hide from immune attack on one hand (loss of
CIITA leading to down-regulation of HLA-DR) while up-
regulating the ligands of PD-1 that antagonize the T cell
immune response to the tumor on the other. The ﬁnding of
these novel genetic mechanisms now identiﬁes obvious
candidate tumors and speciﬁc patients likely to beneﬁt from
targeted approaches using antibody-based therapies that
disrupt PD-1 signaling pathways [15].REFERENCES
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STATE OF SALVAGE THERAPY FOR RELAPSED AND
PRIMARY REFRACTORY DIFFUSE LARGE B CELL
LYMPHOMA
Craig Moskowitz
The CORAL (Collaborative Trial in Relapsed Aggressive
Lymphoma) intergroup trial compared rituximab, ifosfa-
mide, etoposide, and carboplatin (R-ICE) with rituximab,
dexamethasone, cytarabine, and cisplatin (R-DHAP) for
patients with relapsed and primary refractory diffuse large B
cell lymphoma (DLBCL). The overall response rate was 63%;
38% of patients achieved complete response as determined
by CT criteria. There was no difference between the response
rates in the R-ICE (63.5%; conﬁdence interval: 56% to 70%)
and R-DHAP (62.8%; conﬁdence interval: 55% to 69%) groups
or in the mobilization-adjusted response rates (52% versus
54%, respectively) [1,2].
Prior exposure to rituximab predicted for response rate
(51% in rituximab treated versus 83% in rituximab naive
patients) in the CORAL study. It is interesting that a response
rate of 83% conﬁrms the original report of R-ICE in rituximab-
naive patients [3]. However, because all patients in the
United States with DLBCL receive rituximab as part of
primary therapy, a benchmark of 51% should be considered
the starting point for any new salvage program; however,
other prognostic factors can improve or more likely worsen
these numbers.
Remission duration of <1 year and a second-line age-
adjusted international prognostic index (IPI) >1 also had
a negative impact on response rate, 46% versus 88% for
remission duration and 52% versus 71% for second-line IPI
[4]. One can imagine a number of scenarios where salvage or
second-line therapy followed by High-Dose Therapy/Autol-
ogous Stem Cell Transplant may not be the correct treatment
for these patients. A simple example is a 56-year-old man, 7
months post-therapy with R-CHOP-21, who develops aden-
opathy above and below the diaphragm with an elevated
lactate dehydrogenase. If outcome is analyzed by intent to
treat, the patient has at best a 20% cure rate. Response rate to
RICE or R-DHAP is approximately 50% and, if chemosensitive,
a 40% chance of 3-year progression-free survival.
Recently, Cuccuini et al. reported a secondary analysis
from the CORAL study that can further reduce the likelihood
of curability for this patient population [5]. Up to 10% of
patients with DLBCL have a MYC/8q24 oncogene rearrange-
ment; 150 patients had their pathology specimen analyzed
with ﬂuorescein in situ hybridization probes for MYC/8q24,
BCL2/18q21, and BCL6/3q27. These results were then corre-
lated to clinical characteristics and immunohistochemistry
for CD10, BCL6, MUM1, FOXP1, and BCL2 expression. Twenty-
four cases (16%) had a MYC rearrangement associated with
either a BCL2/18q21 rearrangement (n ¼ 16) or a BCL6/3q27
rearrangement (n¼ 4), so-called double-hit DLBCL [6]. MYCþ
rearrangement was associated with a germinal center B cell
type (GCB) phenotype and high-risk second-line age-
adjusted IPI. Outcome of patients with MYCþ DLBCL was
signiﬁcantly worse than MYC DLBCL, with a 4-year
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a 4-yeay overall survival at 33% versus 62% (P ¼ .02). The
outcome was not inﬂuenced by type of salvage therapy.
The cell of origin has also been evaluated by Thieblemont
et al. in patients on the CORAL trial and GCB patients had an
improved outcome with R-DHAP as long as there was no
evidence of overexpression of MYC [7]. To summarize, any
patient with an activated B cell type subtype or those with
a GCB subtype and overexpression of MYC is considered to
have pathologically unfavorable disease.
At the time of workup of the relapsed/refractory DLBCL, it
is evident from the CORAL trial that patients with remission
duration of <1 year, second-line age-adjusted IPI of 2 or 3,
activated B cell type subtype DLBCL, or MYCþ DLBCL with
a GCB phenotype are unlikely to do well with standard
salvage therapy and an autotransplant with BEAM (BCNU,
etoposide, ara-C, melphalan)-type conditioning regimens.
This is approximately 70% of patients who are transplant
eligible for relapsed and refractory DLBCL. Studies evaluating
immunotherapy post-transplantation, including allo-
transplantation, new conditioning regimens with radio-
immunotherapy, and other combinations of chemotherapy
for salvage treatment, are needed.
A number of centers use and are studying gemcitabine or
oxaliplatin-based salvage regimens; these regimens can be
administered as an outpatient, which is certainly appealing.
The National Cancer Institute of Canada has evaluated gem-
citabine, cisplatin, and rituximab (R-GDP). The response rates
are similar to R-DHAP, but it is better tolerated [8]. A large
phase III trial comparing R-GDP and R-DHAP will be pre-
sented at the American Society of Hematology meetings in
2012. Encouraging results have been reported with the
combination of rituximab, gemcitabine, and oxaliplatin
(R-GEMOX). The French lymphoma study groups treated 46
patients with R-GEMOX and after four cycles the response
rate was 83%, of which 50% of patients achieved a complete
response [9]. The treatment was generally well tolerated;
whether these results will hold up in a patient population
that failed rituximab needs to be studied. Another interesting
approach is a variation of DHAP, which substitutes oxalipla-
tin for cisplatin, referred to as the R-DHAX regimen. Lignon
et al. treated 91 patients with the regimen of which 20% had
baseline renal dysfunction and 42 patients had DLBCL. The
response rate was 77% regardless of prior rituximab therapy;
this program can also be administered as an outpatient [10].
Our current approach is somewhat different in that we
are using an alternative anti-CD20, ofatumomab, with stan-
dard salvage chemotherapy and have recently led a multi-
center phase II trial combining ofatumumab and DHAP or ICE
[11] that showed promising activity with an ORR of 61%.
Treatment was fairly well tolerated, with no unexpected
toxicity, and stem cell mobilizationwas adequate. The results
were promising in the subset of patients with primary
refractory or early-relapsing disease, a group that did less
well on the CORAL study. To see whether ofatumumab is
superior to rituximab in the salvage setting, a phase III
randomized trial of ofatumumab and DHAP and rituximab
and DHAP is ongoing.
Several novel targeted agents are currently under study,
many of which are downstream of the B cell receptor,
including spleen tyrosine kinase (syk) [12], which modulates
and enhances the signal from the receptor. Additional targets
downstream from syk are also being studied, the most
exciting of which are inhibitors of Bruton’s tyrosine kinase,
such as ibrutinib and phosphatidylinositol 3-kinaseinhibitors [13,14]. These oral agents have little single-agent
toxicity, and phase II studies are being initiated to combine
these inhibitors with standard salvage therapy. Finally,
a number of antibody-drug or toxin conjugates are in various
stages of testing. For example, one trial is combining inotu-
zumab ozogamicin, a humanized anti-CD22 antibody
conjugated to the toxin, and calicheamicin with rituximab,
gemcitabine, and oxaliplatin (R-Gem Ox) [15].
In summary, current second-line or salvage therapy is
inadequate in the R-CHOP era. Newer regimens such as those
described above are urgently needed.REFERENCES
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HEMATOPOIETIC STEM CELL TRANSPLANTATION
CONDITIONING REGIMENS AND POST-TRANSPLANT
MAINTENANCE THERAPY FOR DIFFUSE LARGE B-CELL
LYMPHOMA
Thomas C. Shea
Since 1995, when the Parma trial reported a 46% 5-year
event-free survival for patients who received salvage
Table 1
Methods to Improve Hematopoietic Stem Cell Transplant Outcomes for
DLBCL
Interventions Outcomes
Autologous conditioning regimens
BEAM “Standard”: low morbidity and
3-5% mortality [5,6]
131I Tositumomab þ BEAM Large randomized negative study
[9]
90Y ibritumomab tiuxetan þ
BEAM
Phase II and a small positive
randomized study [10,11]
Busulfan þ cyclophosphamide þ
VP-16
More toxicity, no deﬁnite beneﬁt
compared with BEAM [8]
TBI-containing regimens Increased early and late toxicities;
no survival beneﬁt [12,13]
Allogeneic transplant regimens
Fully ablative regimens Increased transplant-related
mortality outweighs beneﬁt as
initial therapy but may be
effective salvage therapy
[15-17]
Reduced-intensity regimens Effective as salvage after
autologous HSCT [17]
Tandem auto/allo HSCT Promising phase I/II data for
high-risk disease [14]
Maintenance regimens
Effective phase II salvage
regimens
Ibrutinib, inotuzumab ozogamicin
[20,21]
Phase II maintenance regimens Anti-PD1 antibody, CT-011 [22]
Rituximab Overall ineffective in phase III trial
[18]
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versus 12% for those receiving chemotherapy alone, the
standard of care for patients with relapsed diffuse large B cell
lymphoma (DLBCL) has been salvage therapy followed by
autologous HSCT [1]. Since that landmark report, the addi-
tion of the anti-CD20 antibody, rituximab, has led to an
approximately 20% improvement in event-free survival after
initial anthracycline-based chemotherapy for these patients
[2]. Despite these advances, nearly 50% of all patients with
DLBCL will eventually relapse with their disease, at which
point salvage therapy with autologous stem cell trans-
plantation remains the best option for cure in this
population.
Hamlin and colleagues at Memorial Sloan Kettering re-
ported that the secondary age-adjusted international prog-
nostic index (saaIPI) using stage of disease, performance
status, and lactate dehydrogenase at the time of relapse were
important predictors for eventual outcome [3]. More recent
data have identiﬁed the value of a negative positron emission
tomography scan before transplant [4], and the CORAL
(Collaborative Trial in Relapsed Aggressive Lymphoma) study
has shown that failure after the use of rituximab in the initial
treatment, primary refractory disease, relapse within a year
of initial diagnosis, or saaIPI >1 were also associated with
a poor outcome [5]. Three-year event-free survival rates in
this trial were 21%, 20%, and 18% for those who had been
treated with previous rituximab, had relapsed within 12
months of diagnosis, or those with saaIPI scores of 2 to 3,
respectively, versus 47%, 45%, and 40% for those without
these characteristics. Only about 50% of these high-risk
patients were able to achieve a complete or partial remis-
sion to salvage therapy. Forty percent of this chemotherapy-
responsive populationwas able to achieve durable remission
with transplantation, but this constituted only 20% of the
entire high-risk group. Other biological factors such as the
activated B cell type versus germinal center B cell type
phenotypes and the presence of MYC translocations are
outlined in the articles Biology of Diffuse Large B Cell
Lymphomas and State of Salvage Therapy for Relapsed and
Primary Refractory Diffuse Large B Cell above [6]. Clearly,
new treatment strategies that include better salvage and
more effective transplant regimens are needed.
Autologous HSCT Conditioning Regimens
Although the most common transplant regimen in use is
the combination of BCNU, etoposide, cytarabine, and
melphalan, or BEAM, there have been many other efforts to
improve on the efﬁcacy of this treatment program [7], but no
large comparative studies have documented a superiority of
one regimen over another (Table 1). A number of investiga-
tors have evaluated the busulfanecyclophosphamideeVP-16
regimen, which has shown promise in phase II trials but has
not been compared in a head to head fashion with the
generally less toxic BEAM regimen [8]. 131I Tositumomab
radioimmunotherapy was added to the BEAM regimen in
a recent prospective, randomized Clinical Trials Network trial
and showed no signiﬁcant improvement in overall outcome
compared with BEAM plus rituximab [9]. The addition of 90Y
ibritumomab tiuxetan has shown interesting phase II data.
One small phase III trial of 43 patients comparing 90Y ibri-
tumomab tiuxetan plus BEAM with BEAM indicated
a signiﬁcant overall survival advantage (91% versus 62%
overall survival at 2 years) for 90Y ibritumomab tiuxetan plus
BEAM [10]. In another report from the City of Hope, 90Y
ibritumomab tiuxetan was administered along with BEAMand compared with a total body irradiation (TBI)eVP-
16ecyclophosphamide regimen used at that institution [11].
The 90Y ibritumomab tiuxetan-BEAM regimen had substan-
tially less toxicity and superior overall outcomes compared
with the TBI regimen. Although this trial suggested the
potential value of adding radioimmunotherapy, the trial also
demonstrated the increased early toxicities such asmucositis
as well as the late toxicities including myelodysplasia, cata-
racts, and dry mouth observed in the TBI-treated patients
[12,13]. These side effects have been noted in other large
series and, in conjunction with a general lack of additional
long-term beneﬁt after TBI-based regimens, have resulted in
a general reduction in the use of radiation containing regi-
mens for autologous HSCTs for lymphoma in recent years.
Allogeneic HSCT
It is tempting to look at the outcomes of allogeneic HSCT
regimens for patients with high-risk disease such as those
identiﬁed in the CORAL study (Table 1). Although phase II
studies have shown that reduced-intensity allogeneic HSCTs
are generally well tolerated after failure of autologous HSCTs
and can be used in conjunction with autologous HSCTs as
a tandem auto/allo approach, registry data indicate that
outcomes are comparable or better with a single autologous
as compared with an initial allogeneic HSCT [14-17]. An
alternative strategy that uses an autologous HSCT and then
a non-ablative or reduced-intensity transplant at the time of
subsequent relapse may be more effective. A large report
from the Center for International Blood and Marrow Trans-
plant Research (CIBMTR) compared 877 patients who had
undergone an initial autologous HSCT with 79 patients who
underwent allogeneic HSCT between 1995 and 2003 [15].
The allogeneic patients had higher risk features, including
more advanced stage and more prior therapy, but also
demonstrated a signiﬁcant increase in treatment-related
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rable risk of disease progression compared with the autolo-
gous HSCT patients. Although they concluded that the results
with allogeneic HSCT appeared better than might have been
expected with a comparable population of patients under-
going autologous HSCT, the high treatment-related mortality
and lack of clear beneﬁt has led to the conclusion that
survival after autologous HSCTs was generally better than
with allogeneic HSCTs even with follow-up out to 7 years or
more.
The CIBMTR [16] and the European Group for Blood and
Marrow Transplantation described outcomes with allogeneic
HSCT for DLBCL patients who had failed a previous autolo-
gous HSCT [17]. In the European Group for Blood andMarrow
Transplantation report, 101 patients were evaluated and
found to have a 41.7% relapse-free and 53.8% overall survival
at 3 years. Treatment-related mortality was higher in
patients over the age of 45 and in those who had recurred
less than 12 months after their initial transplant or in those
with refractory disease. Reduced-intensity transplants were
associated with a trend toward a lower mortality and
a higher relapse rate but without any signiﬁcant differences
in progression-free or overall survival between these
approaches regardless of whether this was with a related or
unrelated donor. Perhaps the identiﬁcation of high-risk
patients as deﬁned in the CORAL study or other biological
features such asMYC translocationwill identify patients who
might beneﬁt from early allogeneic HSCT as part of well-
designed clinical trials [7].
Maintenance Therapy after Autologous HSCT
Despite some favorable phase II reports, the use of
maintenance therapy has not been explored in a systematic
fashion after autologous stem cell transplantation. In an
effort to address this issue, the CORAL trial randomized
patients to rituximab maintenance or no maintenance after
their initial transplant [18]. Across the entire group of
patients there was no advantage for the use of rituximab, but
there was an improvement for women who received ritux-
imab versus those who did not. It has been reported that this
may in part be due to enhanced clearance of rituximab in
men, resulting in decreased efﬁcacy because of its shorter
half-life [19]. Although other agents that have activity and
modest toxicity are being considered, such as the Btk
inhibitor, ibrutinib [20], the anti-CD22 immunoconjugate
inotuzumab ozogamicin [21], or the anti PD-1 antibody [22]
CT-011, there are no standard approaches to maintenance
therapy in this setting. The Alliance for Clinical Trials in
Oncology and the Clinical Trials Network are currently
developing a trial to explore this question with an antici-
pated goal of being open in 2013.
Summary
A number of transplant approaches have been tried in
patients with DLBCL following relapse after initial induction
therapy, and there are data that a single autologous HSCT
can cure 20% to 40% or of these patients, depending on their
chemosensitivity and clinical and biological prognostic
factors [5-11,15]. There are registry data indicating that
although allografts are potentially curative after failure of an
autologous HSCT, there are no data indicating that outside
of a clinical trial, allogeneic HSCTs should be preferred over
autologus transplants as initial transplant therapy after
induction failure. Fianlly, whereas maintenance therapiesare attractive after transplant for high-risk DLBCL patients, it
is not yet clear that this approach will demonstrate the
beneﬁt that has been seen in other settings such as for
multiple myeloma patients after treatment with lenalido-
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In this supplement the authors have outlined some of the
important recent advances and areas for future investigation
that will shape our current and future treatments of DLBCL.
With a better understanding of the biology of this distinct yet
heterogeneous group of diseases, we will more precisely
classify the disease that each patient has and develop speciﬁc
treatments to improve the results of both initial and salvage
therapy. Improved classiﬁcation schemas and therapeutic
interventions based on speciﬁc disease biology should then
lead to more effective application of both autologous and
allogeneic HSCTs for these patients. It is hoped that these
approaches, coupled with maintenance therapies such as
those that have prolonged survival after autologous HSCT for
multiple myeloma, will enhance the curability of DLBCL as
well.
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